Samarium 153 Lexidronam Clinical Trials

• Study of Samarium Sm-153 Lexidronam Combined with Docetaxel for Patients with Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00121095 - Recruiting
  Prostatic Neoplasms
  
• Samarium Sm 153 Lexidronam Pentasodium and Autologous Stem Cell Transplant Followed By Radiation Therapy in Treating Patients With Recurrent or Refractory, Metastatic, or Unresectable Osteosarcoma
  ClinicalTrials.gov Identifier: NCT00245011 - Recruiting
  Sarcoma
  
• Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00478075 - Recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain
  ClinicalTrials.gov Identifier: NCT00482378 - Active, not recruiting
  Multiple Myeloma and Plasma Cell Neoplasm; Pain
  
• Samarium Sm 153 Lexidronam Pentasodium With or Without Vaccine Therapy and GM-CSF in Treating Patients With Prostate Cancer and Bone Metastases
  ClinicalTrials.gov Identifier: NCT00450619 - Recruiting
  Metastatic Cancer; Pain; Prostate Cancer
  
• Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00551525 - Not yet recruiting
  Prostate Cancer
  
• Repeated Bone Marrow Transplantation in Treating Patients With Advanced Breast Cancer
  ClinicalTrials.gov Identifier: NCT00003086 - Active, not recruiting
  stage IV breast cancer
  
• Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00316940 - Active, not recruiting
  Multiple Myeloma and Plasma Cell Neoplasm
  
• Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00328614 - Recruiting
  Prostate Cancer
  
• Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
  ClinicalTrials.gov Identifier: NCT00365105 - Recruiting
  Breast Cancer; Lung Cancer; Metastatic Cancer; Pain; Prostate Cancer
  
• Effect of Samarium on the Relief of Pain Due to Vertebral Metastases
  ClinicalTrials.gov Identifier: NCT00374751 - Recruiting
  Cancer; Metastasis; Pain
  
• Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00559429 - Recruiting
  Prostate Cancer
  
• Omr-IgG-am™ (Trademark) for Treating Patients with or at High Risk for West Nile Virus Disease
  ClinicalTrials.gov Identifier: NCT00069316 - Active, not recruiting
  West Nile Virus
  
• A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron™ (Trademark)) in Children with Diffuse Pontine Gliomas
  ClinicalTrials.gov Identifier: NCT00036569 - Recruiting
  Glioma
  
• Trial of Docetaxel-Samarium in Patients with Hormone-Refractory Advanced Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00126230 - Terminated
  Prostate Cancer
  
• Aldara™ (Trademark) (Imiquimod) Cream to Treat Basal Cell Carcinoma
  ClinicalTrials.gov Identifier: NCT00045851 - Completed
  Basal Cell Carcinoma